CION Ameerpet
Sézary syndrome is a rare, leukaemic form of cutaneous T-cell lymphoma, marked by widespread red, itchy skin, enlarged nodes and malignant cells in the blood. This guide explains the symptoms, how it is diagnosed, and how CION's lymphoma team plans treatment.
Sézary syndrome is a rare, aggressive form of cutaneous T-cell lymphoma (CTCL) — a lymphoma that begins in the skin-homing T-cells of the immune system. It sits at the leukaemic, advanced CTCL end of the spectrum and is defined by a classic triad: widespread red, itchy skin (erythroderma), enlarged lymph nodes, and malignant T-cells — called Sézary cells — circulating in the bloodstream.
Because the lymphoma cells travel in the blood, Sézary syndrome behaves as a systemic disease, not a localised skin problem. This is what sets it apart from mycosis fungoides, the most common CTCL, which usually stays confined to the skin for years. Both belong to the wider family of T-cell lymphomas.
This guide walks through the symptoms, how the diagnosis is confirmed with skin and blood testing, and how it is treated. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
Sézary syndrome is named after the French dermatologist Albert Sézary, who first described the abnormal circulating cells (now called Sézary cells) in 1938. Together with mycosis fungoides, it makes up the majority of cutaneous T-cell lymphomas — but Sézary syndrome itself is far rarer, accounting for only a small fraction of all CTCL cases. Its defining feature is that the malignant T-cells are found in the blood, which is why blood testing is central to the diagnosis. (Source: WHO classification of lymphoid tumours, as referenced in NCCN and ESMO CTCL guidelines.)
The most recognisable Sézary syndrome symptoms affect the skin, but because it is a systemic disease, other features appear too. These signs often overlap with eczema and psoriasis, which is why diagnosis can be delayed.
A widespread red, itchy rash has many ordinary causes and most are not lymphoma. But a rash that is widespread, persistent and does not settle with usual eczema or psoriasis treatment deserves specialist review. Speak to a CION specialist if you have these signs or a confirmed diagnosis.
Sézary syndrome is rare and complex — accurate blood-based diagnosis and coordinated, multidisciplinary treatment matter more here than in most lymphomas.
We arrange the full workup — skin biopsy, flow cytometry to count Sézary cells, and T-cell receptor clonality testing — so the diagnosis and stage are pinned down accurately before any treatment decision, in line with NCCN and ESMO guidance.
Every case is reviewed by haematology, radiation and dermato-oncology experts together. This matters because treatment usually combines skin-directed, systemic and blood-directed therapies.
CION delivers radiation, systemic immunotherapy, chemotherapy and supportive care directly. When an allogeneic stem-cell transplant is the right option, it is coordinated with accredited partner facilities.
You deserve a plan built around healing, not billing. Our lymphoma specialists offer a free written second opinion on your biopsy and blood results, with transparent costs explained up front.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a Sézary syndrome diagnosis, want to understand what your Sézary cell count means, or need a second opinion before treatment? CION's lymphoma team is here.
Because the skin changes can look like eczema or psoriasis, diagnosing Sézary syndrome relies on combining the clinical picture with laboratory testing. CION delivers the biopsy coordination, blood analysis and multidisciplinary review directly.
A skin biopsy is examined by a pathologist for the abnormal T-cells typical of CTCL. Because the appearance can be subtle in erythrodermic disease, more than one biopsy is sometimes needed, and results are always read alongside the blood findings.
Sézary syndrome is confirmed largely on the blood. Flow cytometry counts the malignant Sézary cells and looks for an expanded, abnormal T-cell population — typically a raised Sézary cell count, an elevated CD4:CD8 ratio, or loss of normal T-cell markers such as CD7 or CD26. This is what confirms the "advanced CTCL", blood-involved nature of the disease.
T-cell receptor (TCR) gene rearrangement testing confirms that the same single (clonal) T-cell population is present in both skin and blood. Imaging, and sometimes a lymph-node or bone-marrow assessment, complete the staging. NCCN and ESMO recommend this combined skin-plus-blood workup before treatment is planned.
In Sézary syndrome, the diagnosis hinges on the blood, not just the skin. Per NCCN and ESMO guidance, a defining criterion is a significant number of malignant Sézary cells circulating in the bloodstream, alongside markers such as an elevated CD4:CD8 ratio or loss of the T-cell markers CD7 and CD26. This is why flow cytometry and T-cell receptor clonality testing — not a skin biopsy alone — are essential to separate Sézary syndrome from skin-limited mycosis fungoides.
Because Sézary syndrome is a systemic disease with blood involvement, treatment usually combines several approaches rather than skin-directed treatment alone. The plan depends on disease burden, blood tumour load and overall fitness, and every case is reviewed by CION's multidisciplinary tumour board before it is set. For the full treatment pathway, see Lymphoma Treatment in Hyderabad. The main building blocks are:
Skin-directed therapy helps control the erythroderma and relieve itching. For more resistant disease, CION delivers precision radiation therapy (IMRT) directly, and total-skin electron-beam radiation may be discussed as part of coordinated specialist radiation care to treat the whole skin surface.
Extracorporeal photopheresis treats the malignant cells circulating in the blood and is often used in Sézary syndrome, either on its own or combined with other therapies. It is generally well tolerated and aims to reduce the blood tumour burden over time.
CION's team delivers systemic immunotherapy and monoclonal antibody therapy — for example, antibodies directed at markers such as CD30 or CCR4 — along with targeted agents and, for aggressive disease, chemotherapy, all in-house. We describe therapy by drug class; specific regimen choices are individualised and discussed on the Treatment page and in your consultation.
For selected younger, fit patients, an allogeneic stem-cell transplant offers the best chance of durable, long-term remission. This is a specialist procedure that CION coordinates through accredited partner facilities rather than delivering in-house, with continuity of care before and after.
Sézary syndrome is generally considered a treatable but not routinely curable disease. For most people the realistic goal is long-term control of the skin symptoms and blood tumour burden, with a meaningfully improved quality of life. It is more aggressive than skin-limited mycosis fungoides, and published series show that outcomes vary widely by stage, blood tumour load and how well the disease responds to treatment.
For selected younger, fit patients, an allogeneic stem-cell transplant — coordinated through an accredited partner centre — offers the best chance of durable remission. Because every individual is different, figures vary by person, and your CION team will explain the outlook for your specific stage rather than quoting a single number. We never promise a guaranteed cure; our commitment is to honest, evidence-led care aligned with NCCN and ESMO guidance.
Sézary syndrome belongs to the wider family of T-cell lymphomas. If you are researching your diagnosis, these related pages may help.
The most common CTCL and the skin-limited counterpart of Sézary syndrome — usually indolent, staying in the skin as patches and plaques for years.
A plain-language overview of the T-cell lymphoma family, how the subtypes differ and how they are grouped.
A group of mostly nodal T-cell lymphomas that behave differently from the skin-based CTCLs.
A CD30-positive T-cell lymphoma with systemic and primary-cutaneous forms; see also BIA-ALCL.
Sézary syndrome is rare, and its diagnosis and treatment carry real nuance. A second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service through our lymphoma hospital in Hyderabad, with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if blood-based diagnostics have not yet been completed on your case.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Sézary syndrome is a rare, aggressive form of cutaneous T-cell lymphoma (CTCL) — a lymphoma of the skin-homing T-cells. It is considered the leukaemic, advanced end of the CTCL spectrum, and is defined by a classic triad: widespread red, itchy skin covering most of the body (erythroderma), enlarged lymph nodes, and abnormal malignant T-cells (called Sézary cells) circulating in the blood. Because the lymphoma cells travel in the bloodstream, Sézary syndrome behaves as a systemic disease rather than a localised skin problem. It differs from mycosis fungoides, the most common CTCL, which usually stays confined to the skin for years. Learn more on the lymphoma hub.
The hallmark Sézary syndrome symptoms centre on the skin. Most people develop erythroderma — intensely red, inflamed skin over 80% or more of the body — with severe, relentless itching that disturbs sleep. The skin often becomes thick, scaly and peels; the palms and soles may crack (keratoderma), and the eyelids can droop or turn out. Other features include enlarged lymph nodes, hair loss, nail changes and abnormal temperature regulation, so people feel cold and shivery. Because it is advanced CTCL, malignant cells also circulate in the blood. These signs overlap with eczema and psoriasis, which is why diagnosis is often delayed and specialist review matters.
Diagnosis combines the clinical picture with laboratory testing. A skin biopsy is examined by a pathologist, but because the skin changes can look like eczema, the diagnosis leans heavily on blood testing. Flow cytometry counts the malignant Sézary cells and looks for an expanded, abnormal T-cell population — typically an elevated Sézary cell count, a raised CD4:CD8 ratio, or loss of normal T-cell markers such as CD7 or CD26. T-cell receptor (TCR) gene rearrangement testing confirms that a single (clonal) T-cell population is present in both skin and blood. Imaging and sometimes a lymph-node or bone-marrow assessment complete staging. NCCN and ESMO recommend this combined skin-plus-blood workup before treatment is planned.
Both are types of cutaneous T-cell lymphoma, but they sit at different points on the spectrum. Mycosis fungoides is the most common CTCL and is usually indolent — it stays in the skin as patches and plaques for years and the blood is typically not involved. Sézary syndrome is the leukaemic, advanced variant: it is defined by erythroderma affecting most of the body, enlarged lymph nodes, and significant numbers of malignant Sézary cells in the bloodstream. In simple terms, Sézary syndrome is a systemic, blood-involved disease, whereas mycosis fungoides is usually a skin-limited one. This distinction directly changes staging, treatment intensity and outlook, which is why accurate blood testing is essential.
Because Sézary syndrome is a systemic disease with blood involvement, treatment usually combines therapies rather than skin-directed treatment alone. Options — chosen by disease burden and fitness — include skin-directed therapy for symptom relief, total-skin radiation and localised radiotherapy (IMRT), photopheresis (extracorporeal photopheresis) that treats circulating cells, systemic immunotherapy and monoclonal antibodies (targeting markers such as CD30 or CCR4), targeted agents, and chemotherapy for aggressive disease. CION delivers radiation, systemic immunotherapy, chemotherapy and supportive care directly, with every case reviewed by a multidisciplinary tumour board. An allogeneic stem-cell transplant — the main potentially long-term option for selected fit patients — is coordinated through accredited partner facilities. For the full pathway, see Lymphoma Treatment in Hyderabad.
Sézary syndrome is generally considered a treatable but not routinely curable disease; the realistic goal for most people is long-term control of symptoms and disease burden, with an improved quality of life. It is more aggressive than skin-limited mycosis fungoides, and published series report that outcomes vary widely by stage, blood tumour burden and response to treatment. For selected younger, fit patients, an allogeneic stem-cell transplant — coordinated through an accredited partner centre — offers the best chance of durable, long-term remission. Every individual is different, so figures vary by person; your CION team will explain the outlook for your specific stage. We never promise a guaranteed cure. Request a free second opinion to understand your options.
The exact cause of Sézary syndrome is not known. It arises when skin-homing T-cells acquire genetic changes and multiply abnormally, then spill into the bloodstream. It is a rare disease that occurs more often in adults over 60 and slightly more often in men. Unlike some cancers, it is not inherited in a predictable way and it is not contagious — you cannot catch it or pass it to family members. No single lifestyle factor has been proven to cause it, and there is no reliable screening test for the general population. Because early Sézary syndrome symptoms mimic common skin conditions, the most useful step is specialist review of any widespread, persistent red, itchy rash that does not settle with usual eczema or psoriasis care.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.